Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

0.8195 +0.0205 (+2.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks GLP-1 Study Milestone with Ethics Review Board Approval
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks GLP-1 Study Milestone with Ethics Review Board Approval
Via CannabisNewsWire
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Approval to Commence Human Pilot Study Evaluating GLP-1, DehydraTECH
Via Investor Brand Network
Topics Intellectual Property
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
Via ACCESSWIRE
Lexaria Awarded New Patents
Lexaria receives new patents in the fields of epilepsy and anti-viral agents 
Via TheNewswire.com
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Approval to Commence Human Pilot Study Evaluating GLP-1, DehydraTECH
Via CannabisNewsWire
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Global Patent Portfolio to 41; Maintains Focus on GLP-1 Clinical Studies for 2024
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Bolsters C-Suite with New CFO Appointment
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Bolsters C-Suite with New CFO Appointment
Via CannabisNewsWire
Lexaria Awarded New Patents
Via ACCESSWIRE
LEXX Stock Earnings: Lexaria Bioscience Beats EPS for Q2 2024
LEXX stock results show that Lexaria Bioscience beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Focusing on ‘Overwhelming Interest’ for GLP-1 Applications of DehydraTECH(TM)
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires Contract Research Organization to Perform Important GLP-1 Human Pilot Study
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires Contract Research Organization to Perform Important GLP-1 Human Pilot Study
Via CannabisNewsWire
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO to Present at the Upcoming 14th Annual LD Micro Invitational
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Achieves 7% Weight Loss; Sets Stage for 8-week Diabetes and Weight Loss Animal Study
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks Huge 2024 Milestone with FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFO
Via CannabisNewsWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFO
Via Investor Brand Network
Topics Intellectual Property
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Banking on DehydraTECH(TM) Technology for Major 2024 Growth
Via Investor Brand Network
Topics Intellectual Property
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance. 
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Banking on DehydraTECH(TM) Technology for Major 2024 Growth
Via CannabisNewsWire
Topics Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires CRO for Second DehydraTECH-Powered GLP-1 Human Pilot Study
Via Investor Brand Network
Topics Intellectual Property
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Commence Diabetes and Weight Loss Animal Study
Via CannabisNewsWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Commence Diabetes and Weight Loss Animal Study
Via Investor Brand Network
Topics Intellectual Property
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.